Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × zimberelimab × Clear all

NCT05177770 2025-05-08

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

16 enrolled 10 charts

Neoplasms, Prostatic Neoplasms